Drug intelligence / Profile preview

Lactobacillus casei pgsA

Development stage: Unknown
Lead developer: MOA Life Plus
Modality: Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
Administration: Oral

Overview

Lactobacillus casei pgsA is a recombinant live bacterial platform technology designed for the surface display of therapeutic antigens. Developed by MOA Life Plus Co. Ltd. and Future & Tech Corp., the system utilizes the poly-gamma-glutamate synthetase A (pgsA) protein from *Bacillus subtilis* as a transmembrane anchoring matrix to express target proteins on the cell surface of *Lactobacillus casei*. Its primary therapeutic application, BLS-M22, expresses a modified human myostatin protein. Upon oral administration, the live bacteria interact with gut-associated lymphoid tissue (GALT) to induce mucosal and systemic immune responses, specifically generating anti-myostatin IgG antibodies. These antibodies neutralize myostatin, a member of the TGF-β superfamily that negatively regulates skeletal muscle growth. By inhibiting myostatin, the therapy aims to preserve muscle mass and improve motor function in patients with muscle-wasting conditions such as Duchenne muscular dystrophy (DMD).

Other names: L. casei-pgsArecombinant Lactobacillus casei pgsA

Targets

GDF8 (Myostatin)

Beyond the preview

Go deeper on Lactobacillus casei pgsA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lactobacillus casei pgsA.

Explore the full profile